Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-0256PMID 28600474PMCID PMC5856249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.

  2017cited by this paper
• "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer."

  2017cited by this paper
• Activation of WNT/beta-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61

  2017cited by this paper
• Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.

  2016cited by this paper
• Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis

  2016cited by this paper
• The role of myeloid cells in cancer therapies

  2016cited by this paper
• Solid stress and elastic energy as measures of tumour mechanopathology

  2016cited by this paper
• Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

  2016cited by this paper
• Transcriptional Control of Dendritic Cell Development.

  2016cited by this paper
• Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature

  2016cited by this paper
• Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61

  2016cited by this paper
• PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity

  2016cited by this paper
• Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages

  2015cited by this paper
• Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

  2015cited by this paper
• Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus.

  2015cited by this paper
• Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

  2015cited by this paper
• TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

  2015cited by this paper
• Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction

  2015cited by this paper
• Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

  2015cited by this paper
• Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

  2014cited by this paper
• The role of mechanical forces in tumor growth and therapy.

  2014cited by this paper
• Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment

  2014cited by this paper
• Role of WNT10A-Expressing Kidney Fibroblasts in Acute Interstitial Nephritis

  2014cited by this paper
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

  2013cited by this paper
• Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

  2013influential reference
• Canonical wnt signaling is required for pancreatic carcinogenesis.

  2013cited by this paper
• Pathway-based personalized analysis of cancer

  2013cited by this paper
• Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer

  2013cited by this paper
• Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

  2013cited by this paper
• Scotty: a web tool for designing RNA-Seq experiments to measure differential gene expression

  2013cited by this paper
• A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2

  2013cited by this paper
• Notch signaling in pancreatic cancer: oncogene or tumor suppressor?

  2013cited by this paper
• The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration

  2013cited by this paper
• Prediagnostic body mass index and pancreatic cancer survival.

  2013cited by this paper
• Angiotensin II drives the production of tumor-promoting macrophages.

  2013cited by this paper
• Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

  2012cited by this paper
• Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

  2012cited by this paper
• Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors

  2012cited by this paper
• Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1

  2012cited by this paper
• Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

  2011cited by this paper
• Angiotensin II revisited: new roles in inflammation, immunology and aging

  2010cited by this paper
• Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

  2010influential reference
• The renin–angiotensin system and cancer: old dog, new tricks

  2010cited by this paper
• Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.

  2009cited by this paper
• AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist

  2009influential reference
• Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.

  2007cited by this paper
• TNF family ligands define niches for T cell memory.

  2007cited by this paper
• Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

  2007cited by this paper
• Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.

  2007cited by this paper
• CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells.

  2005cited by this paper
• Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist

  2001cited by this paper
• Role of extracellular matrix assembly in interstitial transport in solid tumors.

  2000cited by this paper

• 5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation

  2026cites this paper
• Emerging innovations in nanomedicine for cancer immunotherapy

  2025cites this paper
• Strategies for Pancreatic Cancer-Responsive Nanodrug Platforms Targeting Tumor Hypoxic Environments

  2025cites this paper
• Incidental Use of Angiotensin System Inhibitors During Neoadjuvant Therapy for Esophageal Adenocarcinoma: An Analysis of Survival.

  2025cites this paper
• Angiotensin system inhibitors improve survival in patients undergoing pancreatic cancer resection: a meta-analysis of real-world evidence

  2025cites this paper
• The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review

  2025cites this paper
• Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review

  2024cites this paper
• Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

  2024cites this paper
• The concomitant use of the renin–angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center

  2024cites this paper
• Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer

  2024cites this paper
• Cancer and Cardiovascular Disease: The Conjoined Twins

  2024cites this paper
• Cardiovascular/anti‐inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta‐analysis of randomized trials

  2024cites this paper
• The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection

  2024cites this paper
• Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Combination of Losartan and Platinum Nanoparticles with Photothermal Therapy Induces Immunogenic Cell Death Effective Against Neuroblastoma

  2024influential citation
• Impact of Renin-Angiotensin System Inhibitors on Disease Characteristics in Patients with Localized Prostate Cancer Treated with Radical Prostatectomy: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study

  2024cites this paper
• Synergistic effects of calcium channel blockers and renin-angiotensin inhibitors with gemcitabine-based chemotherapy on the survival of patients with pancreatic cancer

  2024cites this paper
• Cancer Metabolism as a Therapeutic Target and Review of Interventions

  2023cites this paper
• The Dual Role of Necroptosis in Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions.

  2023cites this paper
• Survival Benefit of Renin-Angiotensin System Blockers in Critically Ill Cancer Patients: A Retrospective Study

  2023cites this paper
• Identification of novel prognostic circRNA biomarkers in circRNA-miRNA-mRNA regulatory network in gastric cancer and immune infiltration analysis

  2023cites this paper
• Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors

  2023cites this paper
• Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.

  2023cites this paper
• Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?

  2023cites this paper
• The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies

  2023cites this paper
• Desmoplasia in cervical cancer is associated with a more aggressive tumor phenotype

  2023cites this paper
• Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

  2022cites this paper
• Incidence of pancreatic cancer in angiotensin-converting enzyme inhibitors (ACEIs) versus angiotensin receptor blockers (ARBs): a population-based cohort study

  2022cites this paper
• Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer

  2022influential citation
• Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models

  2022cites this paper
• The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.

  2022cites this paper
• Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

  2022cites this paper
• Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies

  2022influential citation
• Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors

  2022cites this paper
• Angiotensin blockade therapy and survival in pancreatic cancer: a population study

  2022cites this paper
• The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up.

  2022cites this paper
• Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors.

  2022cites this paper
• Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

  2022cites this paper
• Cancer-associated Fibroblasts: Origin, Function, Imaging, and Therapeutic Targeting.

  2022cites this paper
• Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates

  2021cites this paper
• The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.

  2021cites this paper
• The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer

  2021cites this paper
• Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects

  2021cites this paper
• Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma.

  2021cites this paper
• Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?

  2021cites this paper
• Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy

  2021cites this paper
• Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.

  2021cites this paper
• Therapeutic targets in the pancreatic adenocarcinoma microenvironment: past challenges and opportunities for the future

  2021cites this paper
• The Renin–Angiotensin System in the Tumor Microenvironment of Glioblastoma

  2021cites this paper
• The renin-angiotensin system in central nervous system tumors and degenerative diseases.

  2021cites this paper
• Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology

  2021cites this paper
• (Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder

  2021cites this paper
• Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

  2020cites this paper
• Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward

  2020cites this paper
• Normalizing the Tumor Microenvironment for Radiosensitization

  2020cites this paper
• Stories of drug repurposing for pancreatic cancer treatment—Past, present, and future

  2020cites this paper
• Renin-Angiotensin System in the Tumor Microenvironment.

  2020cites this paper
• Tumor Microenvironment: Molecular Players – Part B

  2020cites this paper
• Impact of angiotensin system inhibitors on esophageal cancer survival

  2020cites this paper
• Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma

  2020cites this paper
• The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.

  2020cites this paper
• Systemic and targeted therapies for pancreatic ductal adenocarcinoma

  2020cites this paper
• Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study

  2020cites this paper
• Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

  2020cites this paper
• Upregulation of ASPM, BUB1B and SPDL1 in tumor tissues predicts poor survival in patients with pancreatic ductal adenocarcinoma

  2020cites this paper
• Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments.

  2020cites this paper
• Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer

  2019cites this paper
• ACE Inhibitor Therapy Does Not Influence the Survival Outcomes of Patients with Colorectal Liver Metastases Following Liver Resection

  2019cites this paper
• Delivery technologies for cancer immunotherapy

  2019cites this paper
• Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

  2019cites this paper
• Renin–Angiotensin Inhibition in Combating Malignancy: A Review

  2019cites this paper
• Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

  2019cites this paper
• Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.

  2019cites this paper
• Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.

  2019cites this paper
• Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy

  2019cites this paper
• Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges.

  2019cites this paper
• Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.

  2019cites this paper
• Renin angiotensin system and its role in biomarkers and treatment in gliomas

  2018cites this paper
• Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

  2018cites this paper
• Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.

  2018cites this paper
• Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity

  2018cites this paper
• Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study.

  2018cites this paper
• Review article: systemic treatment of hepatocellular carcinoma

  2018cites this paper
• Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis

  2018cites this paper
• Quantifying solid stress and elastic energy from excised or in situ tumors

  2018cites this paper
• Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

  2017cites this paper
• Engineering and physical sciences in oncology: challenges and opportunities

  2017cites this paper